V
15.67
0.44 (2.89%)
| 前收盘价格 | 15.23 |
| 收盘价格 | 15.17 |
| 成交量 | 395,399 |
| 平均成交量 (3个月) | 839,490 |
| 市值 | 1,278,546,688 |
| 价格/销量 (P/S) | 3.79 |
| 股市价格/股市净资产 (P/B) | 3.08 |
| 52周波幅 | |
| 利润日期 | 6 Aug 2025 - 11 Aug 2025 |
| 营业利益率 (TTM) | -130,369.45% |
| 稀释每股收益 (EPS TTM) | -3.35 |
| 总债务/股东权益 (D/E MRQ) | 3.82% |
| 流动比率 (MRQ) | 19.49 |
| 营业现金流 (OCF TTM) | -279.75 M |
| 杠杆自由现金流 (LFCF TTM) | -171.41 M |
| 资产报酬率 (ROA TTM) | -32.62% |
| 股东权益报酬率 (ROE TTM) | -51.95% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | Viridian Therapeutics, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
1.9
| 分析师共识 | 3.0 |
| 内部交易活动 | NA |
| 价格波动 | 1.0 |
| 技术平均移动指标 | 1.5 |
| 技术振荡指标 | 2.0 |
| 平均 | 1.88 |
|
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED). |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 投资方式 | Small Core |
| 内部持股比例 | 0.16% |
| 机构持股比例 | 114.23% |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 45.00 (RBC Capital, 187.17%) | 购买 |
| 中 | 36.00 (129.74%) | |
| 低 | 27.00 (Goldman Sachs, 72.30%) | 购买 |
| 平均值 | 36.00 (129.74%) | |
| 总计 | 5 购买 | |
| 平均价格@调整类型 | 12.84 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Needham | 20 May 2025 | 36.00 (129.74%) | 购买 | 13.82 |
| 07 May 2025 | 36.00 (129.74%) | 购买 | 12.29 | |
| Goldman Sachs | 07 May 2025 | 27.00 (72.30%) | 购买 | 12.29 |
| JMP Securities | 07 May 2025 | 38.00 (142.50%) | 购买 | 12.29 |
| RBC Capital | 07 May 2025 | 45.00 (187.17%) | 购买 | 12.29 |
| HC Wainwright & Co. | 23 Apr 2025 | 34.00 (116.98%) | 购买 | 13.51 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合